Last 12 months
Inside the activity.
5 purchase rows · 5 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 1 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 4 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 3 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 1 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 26, 2018 Filed Dec 27, 2018 22:11 UTC |
Swanson Regg E.Director
|
PurchaseCommon Stock | 100 | $101.05 | $10,105.00 |
DisclosureSEC source: 0001209191-18-064199 · doc4.xml · nonDerivative · entry 1 Swanson Regg E. · CIK 0001412473 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Disclosed balance after: 2,196 F1 · balance_after: Regg E Swanson Revocable Trust is the owner and Beneficiary and Trustee Read SEC document |
| December 11, 2018 Filed Dec 13, 2018 13:52 UTC |
Chapman Harry SDirector
|
PurchaseCommon Stock | 1,200 | $110.69 | $132,828.00 |
DisclosureSEC source: 0001209191-18-062359 · doc4.xml · nonDerivative · entry 1 Chapman Harry S · CIK 0001500817 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,450 F1 · balance_after: Includes 1,000 shares of common stock which was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions will lapse on the 500 shares on each of January 1, 2019 and April 1, 2019. Read SEC document |
| November 16, 2018 Filed Nov 20, 2018 15:57 UTC |
BROOKNER MARK JDirector
|
SaleCommon Stock | 500 | $118.50 | $59,250.00 |
DisclosureSEC source: 0001209191-18-059400 · doc4.xml · nonDerivative · entry 1 BROOKNER MARK J · CIK 0000938954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,625 F1 · balance_after: Includes 1,000 shares of common stock which was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions will lapse on the 500 shares on each of January 1, 2019 and April 1, 2019. Read SEC document |
| November 05, 2018 Filed Nov 6, 2018 16:19 UTC |
BROOKNER MARK JDirector
|
SaleCommon Stock | 2,000 | $113.75 | $227,500.00 |
DisclosureSEC source: 0001209191-18-057318 · doc4.xml · nonDerivative · entry 1 BROOKNER MARK J · CIK 0000938954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,125 F1 · balance_after: Includes 1,000 shares of common stock which was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions will lapse on the 500 shares on each of January 1, 2019 and April 1, 2019. Read SEC document |
| November 02, 2018 Filed Nov 6, 2018 20:20 UTC |
MCAFEE LAWRANCE WDirector · Chief Financial Officer
|
SaleCommon Stock | 3,100 | $113.29 | $351,199.00 |
DisclosureSEC source: 0001209191-18-057342 · doc4.xml · nonDerivative · entry 1 MCAFEE LAWRANCE W · CIK 0001263096 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,507 F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $112.00 - $115.49, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2 · balance_after: Includes 17,629 shares of restricted stock granted under the Company's equity plans. Restrictions lapse as to 3,102 shares on January 1, 2019; 1,852 shares on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020; and 1,142 shares on each of April 1, July 1 and October 1, 2020; 1,157 shares on January 1, 2021; 632 shares on each of April 1, July 1 and October 1, 2021; and 640 shares on January 1, 2022. Read SEC document |
| September 25, 2018 Filed Sep 25, 2018 21:25 UTC |
PULLINS JERALD LDirector
|
GiftCommon Stock | 825 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-052170 · doc4.xml · nonDerivative · entry 1 PULLINS JERALD L · CIK 0001242160 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,671 F1 · shares: Bona Fide gift to daughter of the reporting person. The gift was made without consideration. F2 · balance_after: Includes 1,500 shares of common stock which was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions will lapse on the 500 shares on each of October 1, 2018, January 1, 2019 and April 1, 2019. Read SEC document |
| September 21, 2018 Filed Sep 24, 2018 23:08 UTC |
BROOKNER MARK JDirector
|
SaleCommon Stock | 2,500 | $116.00 | $290,000.00 |
DisclosureSEC source: 0001209191-18-052083 · doc4.xml · nonDerivative · entry 1 BROOKNER MARK J · CIK 0000938954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,125 F1 · balance_after: Includes 1,500 shares of common stock which was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions will lapse on the 500 shares on each of October 1, 2018, January 1, 2019 and April 1, 2019. Read SEC document |
| September 18, 2018 Filed Sep 20, 2018 13:59 UTC |
BROOKNER MARK JDirector
|
GiftCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-051729 · doc4.xml · nonDerivative · entry 1 BROOKNER MARK J · CIK 0000938954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,625 F1 · shares: Shares donated to Charitable Organization F2 · balance_after: Includes 1,500 shares of common stock which was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions will lapse on the 500 shares on each of October 1, 2018, January 1, 2019 and April 1, 2019. Read SEC document |
| September 17, 2018 Filed Sep 18, 2018 21:36 UTC |
Swanson Regg E.Director
|
GiftCommon Stock | 785 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-051519 · doc4.xml · nonDerivative · entry 1 Swanson Regg E. · CIK 0001412473 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Disclosed balance after: 2,096 F1 · shares: Shares donated to a charitable organization. F2 · balance_after: Regg E. Swanson Revocable Trust is the Owner and Regg E. Swanson is Beneficiary and Trustee. Read SEC document |
| September 07, 2018 Filed Sep 10, 2018 21:33 UTC |
BROOKNER MARK JDirector
|
SaleCommon Stock | 625 | $128.50 | $80,312.50 |
DisclosureSEC source: 0001209191-18-050322 · doc4.xml · nonDerivative · entry 1 BROOKNER MARK J · CIK 0000938954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,625 F1 · balance_after: Includes 1,500 shares of common stock which was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions will lapse on the 500 shares on each of October 1, 2018, January 1, 2019 and April 1, 2019. Read SEC document |
| August 23, 2018 Filed Aug 24, 2018 15:20 UTC |
BROOKNER MARK JDirector
|
SaleCommon Stock | 3,000 | $116.85 | $350,550.00 |
DisclosureSEC source: 0001209191-18-048294 · doc4.xml · nonDerivative · entry 2 BROOKNER MARK J · CIK 0000938954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,250 F1 · balance_after: Includes 1,500 shares of common stock which was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions will lapse on the 500 shares on each of October 1, 2018, January 1, 2019 and April 1, 2019. Read SEC document |
| August 23, 2018 Filed Aug 24, 2018 15:20 UTC |
BROOKNER MARK JDirector
|
SaleCommon Stock | 1,375 | $116.75 | $160,531.25 |
DisclosureSEC source: 0001209191-18-048294 · doc4.xml · nonDerivative · entry 1 BROOKNER MARK J · CIK 0000938954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,250 F1 · balance_after: Includes 1,500 shares of common stock which was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions will lapse on the 500 shares on each of October 1, 2018, January 1, 2019 and April 1, 2019. Read SEC document |
| August 17, 2018 Filed Aug 20, 2018 22:16 UTC |
Trier ClaytonDirector
|
SaleCommon Stock | 1,250 | $115.50 | $144,375.00 |
DisclosureSEC source: 0001209191-18-047667 · doc4.xml · nonDerivative · entry 1 Trier Clayton · CIK 0001319561 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,250 F1 · balance_after: Includes 1,500 shares of common stock which was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions will lapse on the 500 shares on each of October 1, 2018, January 1, 2019 and April 1, 2019. Read SEC document |
| August 14, 2018 Filed Aug 15, 2018 19:31 UTC |
READING CHRISTOPHER JDirector · Chief Executive Officer
|
SaleCommon Stock | 8,768 | $115.57 | $1,013,317.76 |
DisclosureSEC source: 0001209191-18-046737 · doc4.xml · nonDerivative · entry 1 READING CHRISTOPHER J · CIK 0001270356 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,467 F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $115.00 - $116.65, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2 · balance_after: Includes 41,454 shares of restricted stock granted under the Company's equity plans. Restrictions lapse as to 6,206 shares on each of October 1, 2018 and January 1, 2019; 3,706 shares on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020: 2,286 shares on each of April 1, July 1 and October 1, 2020; 2,300 shares on January 1, 2021; and 1,265 shares on each of April 1, July 1 and October 1, 2021 and on January 1, 2022. Read SEC document |
| August 07, 2018 Filed Aug 8, 2018 19:18 UTC |
READING CHRISTOPHER JDirector · Chief Executive Officer
|
SaleCommon Stock | 451 | $115.78 | $52,216.78 |
DisclosureSEC source: 0001209191-18-045799 · doc4.xml · nonDerivative · entry 2 READING CHRISTOPHER J · CIK 0001270356 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,235 F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $115.40 - $116.50, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2 · balance_after: Includes 41,454 shares of restricted stock granted under the Company's equity plans. Restrictions lapse as to 6,206 shares on each of October 1, 2018 and January 1, 2019; 3,706 shares on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020: 2,286 shares on each of April 1, July 1 and October 1, 2020; 2,300 shares on January 1, 2021; and 1,265 shares on each of April 1, July 1 and October 1, 2021 and on January 1, 2022. Read SEC document |
| August 06, 2018 Filed Aug 8, 2018 19:18 UTC |
READING CHRISTOPHER JDirector · Chief Executive Officer
|
SaleCommon Stock | 781 | $116.58 | $91,048.98 |
DisclosureSEC source: 0001209191-18-045799 · doc4.xml · nonDerivative · entry 1 READING CHRISTOPHER J · CIK 0001270356 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,686 F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $116.50 - $117.35, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2 · balance_after: Includes 41,454 shares of restricted stock granted under the Company's equity plans. Restrictions lapse as to 6,206 shares on each of October 1, 2018 and January 1, 2019; 3,706 shares on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020: 2,286 shares on each of April 1, July 1 and October 1, 2020; 2,300 shares on January 1, 2021; and 1,265 shares on each of April 1, July 1 and October 1, 2021 and on January 1, 2022. Read SEC document |
| August 06, 2018 Filed Aug 8, 2018 15:14 UTC |
PULLINS JERALD LDirector
|
SaleCommon Stock | 4,000 | $115.01 | $460,040.00 |
DisclosureSEC source: 0001209191-18-045779 · doc4.xml · nonDerivative · entry 1 PULLINS JERALD L · CIK 0001242160 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,496 F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2 · balance_after: Includes 1,500 shares of common stock which was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions will lapse on the 500 shares on each of October 1, 2018, January 1, 2019 and April 1, 2019. Read SEC document |
| August 03, 2018 Filed Aug 6, 2018 20:26 UTC |
McDowell GlennChief Operating Officer
|
SaleCommon Stock | 6,204 | $114.81 | $712,281.24 |
DisclosureSEC source: 0001209191-18-045527 · doc4.xml · nonDerivative · entry 1 McDowell Glenn · CIK 0001315304 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,731 F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $114.10 - $116.90, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2 · balance_after: Includes 20.731 shares of restricted stock granted under the Company's equity plans. Restrictions lapse as to 3,102 shares on each of October 1, 2018 and January 1, 2019; 1,852 shares on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020; and 1,142 shares on each of April 1, July 1 and October 1, 2020; 1,157 shares on January 1, 2021; 632 shares on each of April 1, July 1 and October 1, 2021; and 640 shares on January 1, 2022. Read SEC document |
| August 03, 2018 Filed Aug 6, 2018 20:24 UTC |
MCAFEE LAWRANCE WDirector · Chief Financial Officer
|
SaleCommon Stock | 3,100 | $115.59 | $358,329.00 |
DisclosureSEC source: 0001209191-18-045526 · doc4.xml · nonDerivative · entry 1 MCAFEE LAWRANCE W · CIK 0001263096 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,607 F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $114.00 - $116.80, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2 · balance_after: Includes 20,731 shares of restricted stock granted under the Company's equity plans. Restrictions lapse as to 3,102 shares on each of October 1, 2018 and January 1, 2019; 1,852 shares on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020; and 1,142 shares on each of April 1, July 1 and October 1, 2020; 1,157 shares on January 1, 2021; 632 shares on each of April 1, July 1 and October 1, 2021; and 640 shares on January 1, 2022. Read SEC document |
| May 22, 2018 Filed May 23, 2018 19:27 UTC |
Harris Bernard A JrDirector
|
GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-032551 · doc4.xml · nonDerivative · entry 1 Harris Bernard A Jr · CIK 0001337906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,422 F1 · shares: The 2,000 shares of common stock was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 500 shares lapsed on each of July 1, 2018, October 1, 2018, January 1, 2019 and April 1, 2019, if he is a director of the Company on those dates. F2 · balance_after: Includes the 2,000 shares discussed in Note 1. Read SEC document |
| May 22, 2018 Filed May 23, 2018 18:16 UTC |
Swanson Regg E.Director
|
GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-032533 · doc4.xml · nonDerivative · entry 1 Swanson Regg E. · CIK 0001412473 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · shares: The 2,000 shares of common stock was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 500 shares lapsed on each of July 1, 2018, October 1, 2018, January 1, 2019 and April 1, 2019, if he is a director of the Company on those dates. F2 · balance_after: Includes the 2,000 shares discussed in Note 1. Read SEC document |
| May 22, 2018 Filed May 23, 2018 18:02 UTC |
Trier ClaytonDirector
|
GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-032529 · doc4.xml · nonDerivative · entry 1 Trier Clayton · CIK 0001319561 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,500 F1 · shares: The 2,000 shares of common stock was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 500 shares lapsed on each of July 1, 2018, October 1, 2018, January 1, 2019 and April 1, 2019, if he is a director of the Company on those dates. F2 · balance_after: Includes the 2,000 shares discussed in Note 1. Read SEC document |
| May 22, 2018 Filed May 23, 2018 18:01 UTC |
PULLINS JERALD LDirector
|
GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-032526 · doc4.xml · nonDerivative · entry 1 PULLINS JERALD L · CIK 0001242160 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,496 F1 · shares: The 2,000 shares of common stock was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 500 shares lapsed on each of July 1, 2018, October 1, 2018, January 1, 2019 and April 1, 2019, if he is a director of the Company on those dates. F2 · balance_after: Includes the 2,000 shares discussed in Note 1. Read SEC document |
| May 22, 2018 Filed May 23, 2018 17:59 UTC |
KUNTZ EDWARD LDirector
|
GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-032524 · doc4.xml · nonDerivative · entry 1 KUNTZ EDWARD L · CIK 0001182168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,750 F1 · shares: The 2,000 shares of common stock was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 500 shares lapsed on each of July 1, 2018, October 1, 2018, January 1, 2019 and April 1, 2019, if he is a director of the Company on those dates. F2 · balance_after: Includes the 2,000 shares discussed in Note 1. Read SEC document |
| May 22, 2018 Filed May 23, 2018 17:58 UTC |
Chapman Harry SDirector
|
GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-032522 · doc4.xml · nonDerivative · entry 1 Chapman Harry S · CIK 0001500817 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,250 F1 · shares: The 2,000 shares of common stock was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 500 shares lapsed on each of July 1, 2018, October 1, 2018, January 1, 2019 and April 1, 2019, if he is a director of the Company on those dates. F2 · balance_after: Includes the 2,000 shares discussed in Note 1. Read SEC document |
| May 22, 2018 Filed May 23, 2018 17:54 UTC |
BROOKNER MARK JDirector
|
GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-032521 · doc4.xml · nonDerivative · entry 1 BROOKNER MARK J · CIK 0000938954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,625 F1 · shares: The 2,000 shares of common stock was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 500 shares lapsed on each of July 1, 2018, October 1, 2018, January 1, 2019 and April 1, 2019, if he is a director of the Company on those dates. F2 · balance_after: Includes the 2,000 shares discussed in Note 1. Read SEC document |
| May 16, 2018 Filed May 17, 2018 20:16 UTC |
BROOKNER MARK JDirector
|
SaleCommon Stock | 1,250 | $91.83 | $114,787.50 |
DisclosureSEC source: 0001209191-18-030885 · doc4.xml · nonDerivative · entry 1 BROOKNER MARK J · CIK 0000938954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,625 Read SEC document |
| May 11, 2018 Filed May 11, 2018 19:51 UTC |
READING CHRISTOPHER JDirector · Chief Executive Officer
|
SaleCommon Stock | 2,672 | $92.16 | $246,251.52 |
DisclosureSEC source: 0001209191-18-029508 · doc4.xml · nonDerivative · entry 3 READING CHRISTOPHER J · CIK 0001270356 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,467 F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $92.00 - $92.60, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2 · balance_after: Includes 47,660 shares of restricted stock granted under the Company's equity plans. Restrictions lapse as to 6,206 shares on each of July 1, 2018, October 1, 2018 and January 1, 2019; 3,706 shares on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020: 2,286 shares on each of April 1, July 1 and October 1, 2020; 2,300 shares on January 1, 2021; and 1,265 shares on each of April 1, July 1 and October 1, 2021 and on January 1, 2022. Read SEC document |
| May 11, 2018 Filed May 14, 2018 16:38 UTC |
KUNTZ EDWARD LDirector
|
SaleCommon Stock | 2,000 | $92.02 | $184,040.00 |
DisclosureSEC source: 0001209191-18-029750 · doc4.xml · nonDerivative · entry 1 KUNTZ EDWARD L · CIK 0001182168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $91.90 - $92.25, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| May 10, 2018 Filed May 11, 2018 19:51 UTC |
READING CHRISTOPHER JDirector · Chief Executive Officer
|
SaleCommon Stock | 8,689 | $92.05 | $799,822.45 |
DisclosureSEC source: 0001209191-18-029508 · doc4.xml · nonDerivative · entry 2 READING CHRISTOPHER J · CIK 0001270356 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,139 F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $92.00 - $92.40, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2 · balance_after: Includes 47,660 shares of restricted stock granted under the Company's equity plans. Restrictions lapse as to 6,206 shares on each of July 1, 2018, October 1, 2018 and January 1, 2019; 3,706 shares on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020: 2,286 shares on each of April 1, July 1 and October 1, 2020; 2,300 shares on January 1, 2021; and 1,265 shares on each of April 1, July 1 and October 1, 2021 and on January 1, 2022. Read SEC document |
| May 09, 2018 Filed May 11, 2018 19:51 UTC |
READING CHRISTOPHER JDirector · Chief Executive Officer
|
SaleCommon Stock | 13,639 | $92.01 | $1,254,924.39 |
DisclosureSEC source: 0001209191-18-029508 · doc4.xml · nonDerivative · entry 1 READING CHRISTOPHER J · CIK 0001270356 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,828 F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $92.00 - $92.10, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2 · balance_after: Includes 47,660 shares of restricted stock granted under the Company's equity plans. Restrictions lapse as to 6,206 shares on each of July 1, 2018, October 1, 2018 and January 1, 2019; 3,706 shares on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020: 2,286 shares on each of April 1, July 1 and October 1, 2020; 2,300 shares on January 1, 2021; and 1,265 shares on each of April 1, July 1 and October 1, 2021 and on January 1, 2022. Read SEC document |
| May 04, 2018 Filed May 7, 2018 18:36 UTC |
MCAFEE LAWRANCE WDirector · Chief Financial Officer
|
Disposition to issuerCommon Stock | 2,900 | $87.42 | $253,518.00 |
DisclosureSEC source: 0001209191-18-028269 · doc4.xml · nonDerivative · entry 2 MCAFEE LAWRANCE W · CIK 0001263096 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,707 F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $87.20 to $87.90, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F1 · balance_after: Includes 23,833 shares of restricted stock granted under the Company's equity plans. Restrictions lapse as to 3,102 shares on each of July 1, 2018, October 1, 2018 and January 1, 2019; 1,852 shares on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020; and 1,142 shares on each of April 1, July 1 and October 1, 2020; 1,157 shares on January 1, 2021; 632 shares on each of April 1, July 1 and October 1, 2021; and 640 shares on January 1, 2022. Read SEC document |
| May 04, 2018 Filed May 7, 2018 18:36 UTC |
MCAFEE LAWRANCE WDirector · Chief Financial Officer
|
Disposition to issuerCommon Stock | 700 | $87.00 | $60,900.00 |
DisclosureSEC source: 0001209191-18-028269 · doc4.xml · nonDerivative · entry 1 MCAFEE LAWRANCE W · CIK 0001263096 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,607 F1 · balance_after: Includes 23,833 shares of restricted stock granted under the Company's equity plans. Restrictions lapse as to 3,102 shares on each of July 1, 2018, October 1, 2018 and January 1, 2019; 1,852 shares on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020; and 1,142 shares on each of April 1, July 1 and October 1, 2020; 1,157 shares on January 1, 2021; 632 shares on each of April 1, July 1 and October 1, 2021; and 640 shares on January 1, 2022. Read SEC document |
| March 16, 2018 Filed Mar 20, 2018 16:06 UTC |
PULLINS JERALD LDirector
|
GiftCommon Stock | 500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-020812 · doc4.xml · nonDerivative · entry 1 PULLINS JERALD L · CIK 0001242160 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,496 F1 · shares: Bona Fide gift to the daughter of the reporting person. The gift was made without consideration. F2 · balance_after: Includes 500 shares of common stock which was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions will lapse on the 500 shares on April 1, 2018. Read SEC document |
| March 15, 2018 Filed Mar 15, 2018 21:27 UTC |
McDowell GlennChief Operating Officer
|
SaleCommon stock | 2,900 | $82.55 | $239,395.00 |
DisclosureSEC source: 0001209191-18-019908 · doc4.xml · nonDerivative · entry 1 McDowell Glenn · CIK 0001315304 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,935 F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $82.10 - $82.90, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2 · balance_after: Includes 26,935 shares of restricted stock granted under the Company's equity plans. Restrictions lapse as to 3,102 shares on each of April 1, 2018, July 1, 2018, October 1, 2018 and January 1, 2019; 1,852 shares on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020; and 1,142 shares on each of April 1, July 1 and October 1, 2020; 1,157 shares on January 1, 2021; 632 shares on each of April 1, July 1 and October 1, 2021; and 640 shares on January 1, 2022. Read SEC document |
| March 14, 2018 Filed Mar 15, 2018 14:59 UTC |
McDowell GlennChief Operating Officer
|
SaleCommon Stock | 1,179 | $83.27 | $98,175.33 |
DisclosureSEC source: 0001209191-18-019764 · doc4.xml · nonDerivative · entry 1 McDowell Glenn · CIK 0001315304 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,835 F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $83.20 - $83.40, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2 · balance_after: Includes 26,935 shares of restricted stock granted under the Company's equity plans. Restrictions lapse as to 3,102 shares on each of April 1, 2018, July 1, 2018, October 1, 2018 and January 1, 2019; 1,852 shares on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020; and 1,142 shares on each of April 1, July 1 and October 1, 2020; 1,157 shares on January 1, 2021; 632 shares on each of April 1, July 1 and October 1, 2021; and 640 shares on January 1, 2022. Read SEC document |
| March 13, 2018 Filed Mar 14, 2018 19:56 UTC |
McDowell GlennChief Operating Officer
|
SaleCommon Stock | 205 | $85.45 | $17,517.25 |
DisclosureSEC source: 0001209191-18-019523 · doc4.xml · nonDerivative · entry 2 McDowell Glenn · CIK 0001315304 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,014 F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $85.45 - $85.55, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2 · balance_after: Includes 26,935 shares of restricted stock granted under the Company's equity plans. Restrictions lapse as to 3,102 shares on each of April 1, 2018, July 1, 2018, October 1, 2018 and January 1, 2019; 1,852 shares on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020; and 1,142 shares on each of April 1, July 1 and October 1, 2020; 1,157 shares on January 1, 2021; 632 shares on each of April 1, July 1 and October 1, 2021; and 640 shares on January 1, 2022. Read SEC document |
| March 12, 2018 Filed Mar 13, 2018 19:02 UTC |
MCAFEE LAWRANCE WDirector · Chief Financial Officer
|
SaleCommon Stock | 2,000 | $86.06 | $172,120.00 |
DisclosureSEC source: 0001209191-18-019095 · doc4.xml · nonDerivative · entry 1 MCAFEE LAWRANCE W · CIK 0001263096 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,307 F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $85.60 - $86.60, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2 · balance_after: Includes 26,935 shares of restricted stock granted under the Company's equity plans. Restrictions lapse as to 3,102 shares on each of April 1, 2018, July 1, 2018, October 1, 2018 and January 1, 2019; 1,852 shares on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020; and 1,142 shares on each of April 1, July 1 and October 1, 2020; 1,157 shares on January 1, 2021; 632 shares on each of April 1, July 1 and October 1, 2021; and 640 shares on January 1, 2022. Read SEC document |
| March 12, 2018 Filed Mar 13, 2018 18:50 UTC |
BROOKNER MARK JDirector
|
GiftCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-019080 · doc4.xml · nonDerivative · entry 1 BROOKNER MARK J · CIK 0000938954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,875 F1 · shares: Shares donated to Charitable Organization F2 · balance_after: Includes 500 shares of common stock granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapsed as to 500 shares on April 1, 2018, if Mr. Brookner is a director of the Company on this date. Read SEC document |
| March 12, 2018 Filed Mar 13, 2018 18:36 UTC |
Harris Bernard A JrDirector
|
SaleCommon Stock | 2,933 | $86.50 | $253,704.50 |
DisclosureSEC source: 0001209191-18-019072 · doc4.xml · nonDerivative · entry 2 Harris Bernard A Jr · CIK 0001337906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,422 F1 · balance_after: Includes 500 shares of common stock which was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions will lapse on the 500 shares on April 1, 2018. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 19:56 UTC |
McDowell GlennChief Operating Officer
|
SaleCommon Stock | 2,538 | $86.16 | $218,674.08 |
DisclosureSEC source: 0001209191-18-019523 · doc4.xml · nonDerivative · entry 1 McDowell Glenn · CIK 0001315304 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,219 F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $86.15 - $86.25, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2 · balance_after: Includes 26,935 shares of restricted stock granted under the Company's equity plans. Restrictions lapse as to 3,102 shares on each of April 1, 2018, July 1, 2018, October 1, 2018 and January 1, 2019; 1,852 shares on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020; and 1,142 shares on each of April 1, July 1 and October 1, 2020; 1,157 shares on January 1, 2021; 632 shares on each of April 1, July 1 and October 1, 2021; and 640 shares on January 1, 2022. Read SEC document |
| March 09, 2018 Filed Mar 12, 2018 16:04 UTC |
MCAFEE LAWRANCE WDirector · Chief Financial Officer
|
SaleCommon Stock | 5,000 | $83.35 | $416,750.00 |
DisclosureSEC source: 0001209191-18-018734 · doc4.xml · nonDerivative · entry 1 MCAFEE LAWRANCE W · CIK 0001263096 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,307 F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $83.05 - $83.55, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2 · balance_after: Includes 26,935 shares of restricted stock granted under the Company's equity plans. Restrictions lapse as to 3,102 shares on each of April 1, 2018, July 1, 2018, October 1, 2018 and January 1, 2019; 1,852 shares on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020; and 1,142 shares on each of April 1, July 1 and October 1, 2020; 1,157 shares on January 1, 2021; 632 shares on each of April 1, July 1 and October 1, 2021; and 640 shares on January 1, 2022. Read SEC document |
| March 09, 2018 Filed Mar 13, 2018 18:58 UTC |
PULLINS JERALD LDirector
|
SaleCommon Stock | 6,100 | $86.54 | $527,894.00 |
DisclosureSEC source: 0001209191-18-019090 · doc4.xml · nonDerivative · entry 1 PULLINS JERALD L · CIK 0001242160 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,996 F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $86.28 - $86.78, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2 · balance_after: Includes 500 shares of common stock which was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions will lapse on the 500 shares on April 1, 2018. Read SEC document |
| March 09, 2018 Filed Mar 13, 2018 18:55 UTC |
READING CHRISTOPHER JDirector · Chief Executive Officer
|
SaleCommon Stock | 12,000 | $86.57 | $1,038,840.00 |
DisclosureSEC source: 0001209191-18-019085 · doc4.xml · nonDerivative · entry 1 READING CHRISTOPHER J · CIK 0001270356 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,467 F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $86.38 - $86.95, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2 · balance_after: Includes 53,866 shares of restricted stock granted under the Company's equity plans. Restrictions lapse as to 6,206 shares on each of April 1, 2018, July 1, 2018, October 1, 2018 and January 1, 2019; 3,706 shares on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020: 2,286 shares on each of April 1, July 1 and October 1, 2020; 2,300 shares on January 1, 2021; and 1,265 shares on each of April 1, July 1 and October 1, 2021 and on January 1, 2022. Read SEC document |
| March 09, 2018 Filed Mar 13, 2018 18:36 UTC |
Harris Bernard A JrDirector
|
SaleCommon Stock | 3,067 | $86.55 | $265,448.85 |
DisclosureSEC source: 0001209191-18-019072 · doc4.xml · nonDerivative · entry 1 Harris Bernard A Jr · CIK 0001337906 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,355 F1 · balance_after: Includes 500 shares of common stock which was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions will lapse on the 500 shares on April 1, 2018. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 19:46 UTC | GrantCommon Stock | 7,619 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-017654 · doc4.xml · nonDerivative · entry 1 REEVE GRAHAM D. · CIK 0001519948 · COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,619 F1 · shares: The 7,619 shares of common stock were granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse in 16 quarterly installment with the first 15 installments of 476 shares each beginning on April 1, 2018 and thereafter with 476 shares on April 1, July 1, October 1 and January 1 of each year with the final 479 shares lapsing on January 1, 2022. F2 · balance_after: See Note (1). Read SEC document |
|
| March 05, 2018 Filed Mar 7, 2018 19:45 UTC |
READING CHRISTOPHER JDirector · Chief Executive Officer
|
GrantCommon Stock | 20,240 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-017653 · doc4.xml · nonDerivative · entry 1 READING CHRISTOPHER J · CIK 0001270356 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,467 F1 · shares: The 20,240 shares of common stock were granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse in 16 quarterly installments of 1,265 shares each beginning on April 1, 2018 and thereafter on April 1, July 1, October 1 and January 1 of each year with the final 1,265 shares lapsing on January 1, 2022. F2 · balance_after: Includes the above mentioned shares and 33,626 of restricted stock granted under the Company's equity plans. Restrictions lapse as to 4,941 on each of April 1, 2018, July 1, 2018, October 1, 2018 and January 1, 2019; 2,441 on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020: $1,021 on each of April 1, July 1 and October 1, 2020; and $1,035 on January 1, 2021. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 19:44 UTC |
McDowell GlennChief Operating Officer
|
GrantCommon Stock | 10,120 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-017652 · doc4.xml · nonDerivative · entry 1 McDowell Glenn · CIK 0001315304 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,757 F1 · shares: The 10,120 shares of common stock were granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse in 16 quarterly installment with the first 15 installments of 632 shares each beginning on April 1, 2018 and thereafter with 632 shares on April 1, July 1, October 1 and January 1 of each year with the final 640 shares lapsing on January 1, 2022. F2 · balance_after: Includes the above mentioned shares and 16,185 shares of restricted stock granted under the Company's equity plans. Restrictions lapse as to 2,470 on each of April 1, 2018, July 1, 2018, October 1, 2018 and January 1, 2019; 1,220 on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020; and 510 on each of April 1, July 1 and October 1, 2020; and 525 on January 1, 2021. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 19:43 UTC |
MCAFEE LAWRANCE WDirector · Chief Financial Officer
|
GrantCommon Stock | 10,120 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-017651 · doc4.xml · nonDerivative · entry 1 MCAFEE LAWRANCE W · CIK 0001263096 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,307 F1 · shares: The 10,120 shares of common stock were granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse in 16 quarterly installment with the first 15 installments of 632 shares each beginning on April 1, 2018 and thereafter with 632 shares on April 1, July 1, October 1 and January 1 of each year with the final 640 shares lapsing on January 1, 2022. F2 · balance_after: Includes the above mentioned shares and 16,185 shares of restricted stock granted under the Company's equity plans. Restrictions lapse as to 2,470 on each of April 1, 2018, July 1, 2018, October 1, 2018 and January 1, 2019; 1,220 on each of April 1, 2019, July 1, 2019, October 1, 2019 and January 1, 2020; and 510 on each of April 1, July 1 and October 1, 2020; and 525 on January 1, 2021. Read SEC document |
| December 27, 2017 Filed Dec 28, 2017 22:10 UTC |
BROOKNER MARK JDirector
|
SaleCommon Stock | 1,375 | $71.22 | $97,927.50 |
DisclosureSEC source: 0001209191-17-067592 · doc4.xml · nonDerivative · entry 2 BROOKNER MARK J · CIK 0000938954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,875 F1 · balance_after: Includes 1,000 shares of common stock granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapsed as to 500 shares on January 1, 2018 and as to 500 shares on April 1, 2018, if Mr. Brookner is a director of the Company on those dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.